文献速递免疫规划慢病防控与筛查

英格兰HPV16/18-AS04疫苗高覆盖率接种实施后监测如何补充其交叉保护效应的证据

How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
PubMed 文献 · Vaccine · 2024-08-29

该文基于英格兰HPV16/18-AS04疫苗接种后监测数据,评估其对相关HPV型的交叉保护效应。监测发现16-18、19-21和22-24岁女性中HPV-31/33/45合并组阳性率分别下降52.3%、67.4%和33.3%,HPV31在各年龄组降至1%以下,未发现对HPV6/11的交叉保护。

要点

  • 英格兰监测显示16-18岁女性HPV-31/33/45合并组下降52.3%。
  • 19-21岁和22-24岁女性分别下降67.4%和33.3%。
  • HPV31阳性率在所有年龄组降至1%以下,未发现对HPV6/11交叉保护。

核心结论

  • 英格兰对疫苗适龄人群型特异性感染的监测提供了HPV16/18-AS04疫苗对高危HPV31/33/45交叉保护的明确证据,与其他国家实施后观察一致,并在某些方面超出临床试验预期。

研究设计与样本

  • 基于英格兰HPV监测中16-18、19-21和22-24岁年轻女性的匿名残留标本数据,并回顾临床试验和其他国家实施后研究。

主要发现

  • 英格兰监测发现16-18岁女性HPV-31/33/45合并组下降52.3%,19-21岁下降67.4%,22-24岁下降33.3%。
  • 型特异性分析显示HPV31阳性率在所有年龄组降至1%以下。
  • 自疫苗接种规划引入以来,交叉保护已被监测并维持超过10年。
  • 英格兰监测结果未发现对HPV6/11的交叉保护。

关键数值与推荐

  • 16-18岁女性HPV-31/33/45合并组下降52.3%。
  • 19-21岁女性HPV-31/33/45合并组下降67.4%。
  • 22-24岁女性HPV-31/33/45合并组下降33.3%。
  • HPV31阳性率在所有年龄组降至1%以下。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bivalent human papillomavirus HPV16/18-AS04 vaccine (Cervarix, GSK) offers direct protection against HPV16/18. Results from randomised controlled trials showed cross protective effects and suggested that declines in some closely related HPV types could be expected in a population with high vaccination coverage. AIM: To evaluate the evidence for cross-protection afforded by HPV16/18-AS04 from post-implementation surveillance in England, and how this complements clinical trial data and post-implementation observations in other countries. METHODS: Evidence of cross-protection in young women offered vaccination with HPV16/18-AS04 was gathered from HPV surveillance in England. Data from clinical trials and other post-implementation studies were reviewed. RESULTS: Surveillance using anonymised residual specimens in England found declines of 52.3%, 67.4% and 33.3% against grouped HPV-31/33/45 in 16-18, 19-21, and 22-24 year olds, respectively. Additionally, type-specific analysis found that the prevalence of HPV31 declined to below 1% across all age groups. Cross-protection has been monitored and maintained for over 10 years since the introduction of the vaccination programme. Cross-protection against HPV6/11 was not found in English surveillance outcomes. CONCLUSION: Surveillance of type-specific infections in vaccine-eligible populations in England has generated clear evidence of cross-protective effects from HPV16/18-AS04 vaccination against high-risk HPV 31/33/45 infections, consistent with other post-implementation observations and confirming and in some ways exceeding expectations from clinical trials.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Navarro-Torné A, Anderson A, Panwar K, et al. How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024. PMID: 39213982. doi:10.1016/j.vaccine.2024.126215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。